These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 31029033)
1. DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors. Shi Y; Jin J; Wang X; Ji W; Guan X Neoplasia; 2019 Jun; 21(6):533-544. PubMed ID: 31029033 [TBL] [Abstract][Full Text] [Related]
2. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells. Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865 [TBL] [Abstract][Full Text] [Related]
3. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer. Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904 [TBL] [Abstract][Full Text] [Related]
4. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619 [TBL] [Abstract][Full Text] [Related]
5. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition. Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743 [TBL] [Abstract][Full Text] [Related]
6. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer. Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912 [TBL] [Abstract][Full Text] [Related]
7. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells. Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187 [TBL] [Abstract][Full Text] [Related]
8. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy. Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975 [TBL] [Abstract][Full Text] [Related]
9. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer. Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182 [TBL] [Abstract][Full Text] [Related]
10. BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression. Li Y; Wang Y; Zhang W; Wang X; Chen L; Wang S Sci Rep; 2021 Feb; 11(1):4774. PubMed ID: 33637776 [TBL] [Abstract][Full Text] [Related]
11. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers. Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948 [TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415 [TBL] [Abstract][Full Text] [Related]
13. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness. De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619 [TBL] [Abstract][Full Text] [Related]
14. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer. Karginova O; Siegel MB; Van Swearingen AE; Deal AM; Adamo B; Sambade MJ; Bazyar S; Nikolaishvili-Feinberg N; Bash R; O'Neal S; Sandison K; Parker JS; Santos C; Darr D; Zamboni W; Lee YZ; Miller CR; Anders CK Mol Cancer Ther; 2015 Apr; 14(4):920-30. PubMed ID: 25824335 [TBL] [Abstract][Full Text] [Related]
16. A Progressively Disassembled DNA Repair Inhibitors Nanosystem for the Treatment of BRCA Wild-Type Triple-Negative Breast Cancer. Fang W; Wang J; Ma X; Shao N; Ye K; Zhang D; Shi C; Luo L Int J Nanomedicine; 2023; 18():6001-6019. PubMed ID: 37901361 [TBL] [Abstract][Full Text] [Related]
17. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910 [TBL] [Abstract][Full Text] [Related]
18. The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition. Xia Q; Cai Y; Peng R; Wu G; Shi Y; Jiang W Int J Oncol; 2014 Mar; 44(3):735-44. PubMed ID: 24378347 [TBL] [Abstract][Full Text] [Related]
19. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer. Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663 [TBL] [Abstract][Full Text] [Related]
20. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer. Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]